Zydus Cadila gets USFDA nod to market breast cancer drug
New Delhi: Drug firm Zydus Cadila said it has received final approval from the United States Food and Drug Administration (USFDA) to market Tamoxifen Citrate Tablets USP in the strengths of 10 mg (base) and 20 mg (base).
It (Tamoxifen Citrate Tablets USP) will be manufactured at the group's formulations manufacturing facility at SEZ in Ahmedabad, the company said in a BSE filing.
The drug is indicated to treat breast cancer, the company said in the filing.
The group now has more than 165 approvals, it added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd